SYK

Business Context and Reporting Period

Company: Stryker Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2000
Business Overview: Stryker operates in two primary segments: Orthopaedic Implants and MedSurg Equipment. The company is integrating its 1998 acquisition of Howmedica and has completed smaller acquisitions in 2000 (Image Guided Technologies, Colorado Biomedical, Neptune System). A 2-for-1 stock split was effective May 12, 2000.

Key Financial Metrics

Note: 1999 figures include significant nonrecurring charges related to the Howmedica acquisition inventory step-up and restructuring.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 10% in Q3 and 9% for the nine-month period compared to 1999. Growth was driven by increased unit volume (8-10%), price increases (1%), and acquisitions (1%), partially offset by unfavorable foreign currency exchange rates.
• Profitability Improvement: The company returned to profitability. Net earnings for the nine months ended Sept 30, 2000, were $154.5 million, a stark contrast to the $24.4 million loss in the same period in 1999. The 1999 loss was heavily impacted by $185.2 million in nonrecurring inventory step-up charges from the Howmedica acquisition.
• Margin Expansion: Gross margin improved significantly to 64.3% (9 months 2000) from 50.0% (9 months 1999). Excluding the 1999 nonrecurring charges, the 1999 margin would have been 38.0%. The 2000 improvement is attributed to cost savings from Howmedica integration and higher selling prices.
• Debt Reduction: Total debt decreased by $172.7 million during the first nine months of 2000. The company repaid $319.0 million against credit facilities while borrowing $167.8 million for working capital needs.

Outlook, Risks, and Management Commentary

• Acquisition Integration: The company continues to integrate Howmedica. Remaining workforce reductions (approx. 1,200 employees) are expected to be completed in Q4 2000. Facility closures in the U.S. are expected to conclude in 2000, with one facility closing in 2001.
• Recent Acquisitions: Completed acquisitions of Image Guided Technologies ($12.0M) and Colorado Biomedical ($7.8M) in 2000. Pro forma results would not differ significantly from reported results.
• Liquidity: Working capital increased to $442.1 million. The company has $250.7 million of additional borrowing capacity available under its $1.65 billion credit facilities. Management believes cash on hand and operating cash flows are sufficient to fund operations and debt repayments.
• Risks:
  • Foreign Currency: Weakening foreign currencies reduced the value of international net assets by $65.3 million in the first nine months of 2000 (recorded in equity, not earnings).
  • Market Risks: Forward-looking statements are subject to risks including economic conditions, foreign exchange fluctuations, and competitive environment changes.
  • Accounting Changes: The company must adopt FASB Statement No. 133 (Derivatives) in Q1 2001; the impact on future results has not yet been determined.

Investor Verification Checklist

• Nonrecurring Charges: Verify the exclusion of the $185.2 million inventory step-up charge in 1999 when comparing year-over-year profitability.
• Debt Maturities: Review the schedule of current maturities ($122.3M in 2000, rising to $148.1M in 2002 and $186.5M in 2003) to assess near-term liquidity requirements.
• Foreign Currency Impact: Monitor the $65.3 million translation loss in equity and the $18.4 million negative impact on international sales revenue due to currency fluctuations.
• Restructuring Reserves: Track the utilization of remaining acquisition-related reserves ($17.3 million total remaining at Sept 30, 2000) for severance and facility closures.
• Stock Split Adjustment: Ensure all per-share data comparisons account for the 2-for-1 stock split effective May 12, 2000.